pyrazines has been researched along with navitoclax in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamamoto, T; Hirohara, M; Masuda, Y; Morimoto, Y; Takada, K; Takeuchi, O; Watanabe, K | 1 |
| Bueno, R; Carrasco, RD; Case, AE; Frank, DA; Garg, S; Gokhale, PC; Griffin, JD; Hung, YP; Knott, A; Kulkarni, P; Lapidot, M; Meng, C; Ni, W; Podar, K; Pozhitkov, A; Saladi, SV; Salgia, R; Sattler, M; Sharma, S; Walker, SR; Weisberg, EL | 1 |
2 other study(ies) available for pyrazines and navitoclax
| Article | Year |
|---|---|
Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2020 |
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Jumonji Domain-Containing Histone Demethylases; Mesothelioma, Malignant; Mice; Pyrazines; Pyrazoles; Pyrimidinones; Sulfonamides; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |